10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2016, 34 15, 2p. Supplement: S- Subject
- Language
- English
- ISSN
- 15277755